abstract |
The present invention provides methods of using death receptor ligands such as Apo-2 ligand / TRAIL polypeptide or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases. Embodiments of the invention include methods of using Apo2L / TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with CD20 antibodies.n n n Apo-2 ligand / TRAIL polypeptide, death receptor antibody, CD20 antibody |